Related Experiment Videos
Nomograms for clinically localized disease. Part III: watchful waiting
Eric Schwartz1, Peter Albertsen
1Division of Urology, University of Connecticut Health Center, Farmington, CT 06030-3955, USA.
Seminars in Urologic Oncology
|May 16, 2002
Summary
This study evaluates a 1998 prostate cancer nomogram for predicting 15-year outcomes based on age and Gleason score. Its accuracy in the current prostate-specific antigen (PSA) testing era requires further investigation.
Area of Science:
- Oncology
- Urology
- Medical Statistics
Background:
- Patients with localized prostate cancer require long-term outcome data for treatment decisions.
- Existing nomograms aid in predicting clinical outcomes.
- A 1998 nomogram predicts 15-year outcomes using age and Gleason score.
Purpose of the Study:
- To assess the continued relevance and accuracy of a 1998 prostate cancer nomogram.
- To evaluate the nomogram's predictive capability in the current prostate-specific antigen (PSA) era.
Main Methods:
- Utilizing a nomogram developed from data predating widespread PSA testing.
- Analyzing patient age and Gleason score at diagnosis for outcome prediction.
- Comparing historical data with contemporary patient outcomes.
Main Results:
- The 1998 nomogram predicts 15-year clinical outcomes without aggressive treatment.
- Predictions are based on age and Gleason score from pre-PSA testing era patients.
- The nomogram's accuracy in the PSA era is yet to be determined.
Conclusions:
- The 1998 nomogram provides a baseline for predicting prostate cancer outcomes.
- Longer follow-up is needed to validate the nomogram in the PSA era.
- Contemporary patient outcomes may be better due to earlier diagnosis via PSA testing.